The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis
Open accessAbstract
BACKGROUND: Real-life data on newer biological and biosimilar agents for moderate-to-severe psoriasis are lacking. OBJECTIVES: To examine safety, efficacy and time to discontinuation (drug survival) of biologics (adalimumab, etanercept, infliximab, secukinumab and ustekinumab) and compare originators with biosimilars (i.e. Enbrel with Benepali, and Remicade with Remsima). METHODS: The DERMBIO registry contains data on all Danish patients with moderate-to-severe plaque psoriasis treated with biologics. We examined patients treated between 1 January 2007 and 31 March 2017. We used Kaplan-Meier survival curves and Cox regression to examine drug survival patterns. RESULTS: A total of 3495 treatment series (2161 patients) were included (adalimumab n = 1332; etanercept n = 579; infliximab n = 333; ustekinumab n = 1055 and secukinumab n = 196). Secukinumab had the highest number of PASI 100 (100% improvement from baseline Psoriasis Area and Severity Index) respondents, but also the lowest drug survival among all the biologics. Ustekinumab had the highest drug survival overall. There were no significant differences in discontinuation risk between originator and biosimilar versions of infliximab or etanercept. Treatment with higher than approved dosages was frequent for all drugs except for adalimumab and secukinumab. Adverse events (predominantly infections) were most frequent for secukinumab compared with the other agents. CONCLUSIONS: Ustekinumab was associated with the highest drug survival, and secukinumab with the lowest, although most patients on secukinumab were non-naïve. Switching from originator to biosimilar had no significant impact on drug survival, and the safety profiles were comparable. Adverse events occurred most frequently with secukinumab. Future studies are warranted to assess the long-term safety of novel biologics for psoriasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61602-x · Cited by 21,320
Secukinumab in plaque psoriasis—results of two phase 3 trials
Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314258 · Cited by 1,997
Jørgensen, K. K., Olsen, I. C., Goll, G. L., Lorentzen, M., Bolstad, N., Haavardsholm, E. A., Lundin, K. E. A., Mørk, C., Jahnsen, J., Kvien, T. K., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30068-5 · Cited by 818
Thaçi, D., Blauvelt, A., Reich, K., Tsai, T.-F., Vanaclocha, F., Kingo, K., Ziv, M., Pinter, A., Hugot, S., You, R., et al. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.05.013 · Cited by 551
Warren, R. B., Smith, C. H., Yiu, Z. Z. N., Ashcroft, D. M., Barker, J. N. W. N., Burden, A. D., Lunt, M., McElhone, K., Ormerod, A. D., Owen, C., et al. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.208 · Cited by 393
Papp, K. A., Gottlieb, A. B., Naldi, L., Pariser, D., Ho, V., Goyal, K., Fakharzadeh, S., Chevrier, M., Calabro, S., Langholff, W., et al. (2015) · PubMed · Cited by 312
Blauvelt, A., Reich, K., Tsai, T.-F., Tyring, S., Vanaclocha, F., Kingo, K., Ziv, M., Pinter, A., Vender, R., Hugot, S., et al. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.08.008 · Cited by 312
van de Kerkhof, P. C. M., Griffiths, C. E. M., Reich, K., Leonardi, C. L., Blauvelt, A., Tsai, T.-F., Gong, Y., Huang, J., Papavassilis, C., & Fox, T. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.03.024 · Cited by 302
Gniadecki, R., Kragballe, K., Dam, T. N., & Skov, L. (2011) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2011.10213.x · Cited by 248
Self-citationGlintborg, B., Sørensen, I. J., Loft, A. G., Lindegaard, H., Linauskas, A., Hendricks, O., Hansen, I. M. J., Jensen, D. V., Manilo, N., Espesen, J., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210742 · Cited by 246
Menter, A., Papp, K. A., Gooderham, M., Pariser, D. M., Augustin, M., Kerdel, F. A., Fakharzadeh, S., Goyal, K., Calabro, S., Langholff, W., et al. (2016) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13611 · Cited by 244
Ahlehoff, O., Skov, L., Gislason, G., Gniadecki, R., Iversen, L., Bryld, L. E., Lasthein, S., Lindhardsen, J., Kristensen, S. L., Torp‐Pedersen, C., et al. (2015) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12768 · Cited by 189
Self-citationInterleukin-17 inhibition: role in psoriasis and inflammatory bowel disease
Hohenberger, M., Cardwell, L. A., Oussedik, E., & Feldman, S. R. (2018) · Journal of Dermatological Treatment · doi:10.1080/09546634.2017.1329511 · Cited by 165
Nast, A., Jacobs, A., Rosumeck, S., & Werner, R. N. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.206 · Cited by 136
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
Egeberg, A. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1610828 · Cited by 101
Self-citationLevin, E., Gupta, R., Brown, G. E., Malakouti, M., & Koo, J. Y. M. (2013) · Journal of Dermatological Treatment · doi:10.3109/09546634.2013.826341 · Cited by 78
Puig, L., López‐Ferrer, A., Vilarrasa, E., & García, I. (2013) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12238 · Cited by 73
Cost Effectiveness of Biologic Therapies for Plaque Psoriasis
Ahn, C., Gustafson, C. J., Sandoval, L. F., Davis, S., & Feldman, S. R. (2013) · American Journal of Clinical Dermatology · doi:10.1007/s40257-013-0030-z · Cited by 68
Ahlehoff, O., Skov, L., Gislason, G., Lindhardsen, J., Kristensen, S. L., Iversen, L., Lasthein, S., Gniadecki, R., Dam, T. N., Torp-Pedersen, C. T., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036342 · Cited by 59
Self-citationZweegers, J., Roosenboom, B., van de Kerkhof, P. C. M., van den Reek, J. M. P. A., Otero, M. E., Atalay, S., Kuijpers, A. L. A., Koetsier, M. I. A., Arnold, W. P., Berends, M. A. M., et al. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14888 · Cited by 51
The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis
Dapavo, P., Vujic, I., Fierro, M. T., Quaglino, P., & Sanlorenzo, M. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.04.068 · Cited by 47
Egeberg, A., Iversen, L., Gniadecki, R., Hvid, L., Dam, T. N., Bryld, L. E., & Skov, L. (2017) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14200 · Cited by 26
Self-citation
Cited by
The Cytokine Mediated Molecular Pathophysiology of Psoriasis and Its Clinical Implications
Singh, R., Koppu, S., Perche, P. O., & Feldman, S. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312793 · Cited by 192
Metadata
- Authors
- Egeberg, A., Ottosen, M. B., Gniadecki, R., Broesby-Olsen, S., Dam, T. N., Bryld, L. E., Rasmussen, M. K., & Skov, L.
- Venue
- British Journal of Dermatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-01-09
- Volume
- 178
- Issue
- 2
- Pages
- 509-519
- ISSN
- 0007-0963 (ISSN-L)
- OpenAlex
- W2765150986
- Cited by
- 284
- References
- 22
- FWCI
- 13.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.